Scienture Holdings Reports 449% Revenue Increase but Faces Net Loss and Liquidity Concerns

Scienture Holdings, Inc. (formerly TRxADE Health, Inc.) reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2026. The company generated revenues of $56,325, a substantial increase from $10,258 in the same period last year, marking a 449% rise. This growth is attributed to the continued ramp-up of wholesale distribution sales of its FDA-approved product, ARBLI™ (SCN-102), which commenced commercialization in the third quarter of 2025. The cost of sales decreased to $2,475 from $9,585, resulting in a gross profit of $53,850 compared to $673 in the prior year.

Despite the increase in revenue, Scienture reported a net loss of $3,402,264 for the quarter, slightly higher than the net loss of $3,063,997 recorded in the same quarter of 2025. The increase in net loss was primarily driven by higher operating expenses, including a notable rise in professional fees, which increased by 126% to $932,552, and research and development expenses, which rose by 38% to $793,984. The company’s total operating expenses remained relatively stable at $3,563,349, down marginally from $3,571,990 in the previous year.

Strategically, Scienture has undergone significant organizational changes, including the divestiture of its legacy subsidiaries, which was completed in April 2025. This move is part of a broader strategy to streamline operations and focus on its core pharmaceutical business. The company is now primarily focused on the development and commercialization of specialty pharmaceutical products, particularly in the cardiovascular and central nervous system sectors. The divestitures are expected to enhance operational efficiency and allow for a more agile decision-making framework.

As of March 31, 2026, Scienture reported total assets of $80,661,705, down from $84,178,330 at the end of 2025. The company’s cash and cash equivalents decreased to $3,542,754 from $6,662,008, reflecting a cash burn rate that raises concerns about liquidity. Current liabilities increased slightly to $2,803,670, resulting in a working capital of approximately $1.97 million. The company has indicated that it may need to raise additional capital to support ongoing operations and fund its product development pipeline.

Looking ahead, Scienture's management remains optimistic about the potential for revenue growth from ARBLI™ and other products in its pipeline. The company plans to continue its commercialization efforts and explore strategic partnerships to enhance its market position. However, the filing also highlights substantial doubt about the company's ability to continue as a going concern, emphasizing the need for additional financing to meet its operational requirements over the next twelve months.